151 related articles for article (PubMed ID: 8575503)
1. Urinary interleukin-1 alpha levels are increased by intravesical instillation with keyhole limpet hemocyanin in patients with superficial transitional cell carcinoma of the bladder.
Jurincic-Winkler CD; Gallati H; Alvarez-Mon M; Sippel J; Carballido J; Klippel KF
Eur Urol; 1995; 28(4):334-9. PubMed ID: 8575503
[TBL] [Abstract][Full Text] [Related]
2. Antibody response to keyhole limpet hemocyanin (KLH) treatment in patients with superficial bladder carcinoma.
Jurincic-Winkler CD; von der Kammer H; Beuth J; Scheit KH; Klippel KF
Anticancer Res; 1996; 16(4A):2105-10. PubMed ID: 8712751
[TBL] [Abstract][Full Text] [Related]
3. [Topical immunotherapy (KLH) vs. chemotherapy (Ethoglucid) in prevention of recurrence of superficial bladder cancer. A prospective randomized study].
Flamm J; Donner G; Bucher A; Höltl W; Albrecht W; Havelec L
Urologe A; 1994 Mar; 33(2):138-43. PubMed ID: 8178408
[TBL] [Abstract][Full Text] [Related]
4. Immunohistological findings in patients with superficial bladder carcinoma after intravesical instillation of keyhole limpet haemocyanin.
Jurincic-Winkler C; Metz KA; Beuth J; Engelmann U; Klippel KF
Br J Urol; 1995 Dec; 76(6):702-7. PubMed ID: 8535712
[TBL] [Abstract][Full Text] [Related]
5. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
[TBL] [Abstract][Full Text] [Related]
6. Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG.
Haaff EO; Catalona WJ; Ratliff TL
J Urol; 1986 Oct; 136(4):970-4. PubMed ID: 3489840
[TBL] [Abstract][Full Text] [Related]
7. Recurrent superficial transitional cell carcinoma of the bladder: adjuvant topical chemotherapy versus immunotherapy. A prospective randomized trial.
Flamm J; Bucher A; Höltl W; Albrecht W
J Urol; 1990 Aug; 144(2 Pt 1):260-3. PubMed ID: 2197428
[TBL] [Abstract][Full Text] [Related]
8. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
[TBL] [Abstract][Full Text] [Related]
9. Urinary interleukin-2 monitoring during prolonged bacillus Calmette-Guerin treatment: can it predict the optimal number of instillations?
de Reijke TM; De Boer EC; Kurth KH; Schamhart DH
J Urol; 1999 Jan; 161(1):67-71. PubMed ID: 10037371
[TBL] [Abstract][Full Text] [Related]
10. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
[TBL] [Abstract][Full Text] [Related]
11. Urinary interleukin-8/creatinine level as a predictor of response to intravesical bacillus Calmette-Guerin therapy in bladder tumor patients.
Rabinowitz R; Smith DS; Tiemann DD; Hudson MA
J Urol; 1997 Nov; 158(5):1728-31; discussion 1731-2. PubMed ID: 9334588
[TBL] [Abstract][Full Text] [Related]
12. Effect of keyhole limpet hemocyanin (KLH) and bacillus Calmette-Guérin (BCG) instillation on carcinoma in situ of the urinary bladder.
Jurincic-Winkler C; Metz KA; Beuth J; Sippel J; Klippel KF
Anticancer Res; 1995; 15(6B):2771-6. PubMed ID: 8669862
[TBL] [Abstract][Full Text] [Related]
13. Keyhole limpet hemocyanin for carcinoma in situ of the bladder: a long-term follow-up study.
Jurincic-Winkler CD; Metz KA; Beuth J; Klippel KF
Eur Urol; 2000; 37 Suppl 3():45-9. PubMed ID: 10828687
[TBL] [Abstract][Full Text] [Related]
14. [Intravesical prevention of recurrence of superficial urinary bladder cancer with BCG and KLH. A prospective randomized study].
Kälble T; Möhring K; Ikinger U; Riedasch G; Staehler G
Urologe A; 1991 Mar; 30(2):118-21. PubMed ID: 2058066
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of murine bladder cancer with keyhole limpet hemocyanin (KLH).
Lamm DL; DeHaven JI; Riggs DR; Ebert RF
J Urol; 1993 Mar; 149(3):648-52. PubMed ID: 8437283
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of local Bacillus Calmette-Guérin treatment in superficial bladder cancer relapsing under Keyhole-Limpet Hemocyanin immunotherapy.
Jurincic-Winkler C; Engelmann U; Beuth J; Klippel KF
Zentralbl Bakteriol; 1995 Oct; 282(4):409-15. PubMed ID: 9810664
[TBL] [Abstract][Full Text] [Related]
17. [Assessment of 8-hydroxy-2'-deoxyguanosine concentrations in bladder cancer patients treated with intravesical BCG instillation].
Kaczmarek P; Błaszczyk J; Fijałkowski P; Sierakowska-Fijałek A; Niemirowicz J; Kasprzak A; Baj Z
Pol Merkur Lekarski; 2005 Oct; 19(112):526-8. PubMed ID: 16379317
[TBL] [Abstract][Full Text] [Related]
18. Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy.
Böhle A; Nowc C; Ulmer AJ; Musehold J; Gerdes J; Hofstetter AG; Flad HD
J Urol; 1990 Jul; 144(1):59-64. PubMed ID: 2193171
[TBL] [Abstract][Full Text] [Related]
19. Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies.
Lamm DL; Dehaven JI; Riggs DR
Eur Urol; 2000; 37 Suppl 3():41-4. PubMed ID: 10828686
[TBL] [Abstract][Full Text] [Related]
20. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer.
De Boer EC; De Jong WH; Steerenberg PA; Aarden LA; Tetteroo E; De Groot ER; Van der Meijden AP; Vegt PD; Debruyne FM; Ruitenberg EJ
Cancer Immunol Immunother; 1992; 34(5):306-12. PubMed ID: 1540977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
